XFOR

SEC source: 0001501697-26-000078 · wk-form4_1791230611.xml · nonDerivative · entry 1

KIRSKE DAVID · CIK 0001276750 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 155,983

F1 · kind: Sale of shares to cover personal income tax obligation upon settlement of restricted stock unit award.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $2.82 to $2.92, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3 · balance_after: Of the shares of common stock reported, 64,418 shares represent restricted stock units.

SEC source: 0001501697-26-000069 · wk-form4_1786651821.xml · nonDerivative · entry 1

Craig Adam R · CIK 0001339498 · Director · Executive Chairman

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 328,651

F1 · kind: Sale of shares to cover personal income tax obligation upon settlement of restricted stock unit award.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $4.33 to $4.55, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3 · balance_after: Of the shares of common stock reported, 193,254 shares represent restricted stock units.

SEC source: 0001501697-26-000070 · wk-form4_1786651978.xml · nonDerivative · entry 1

Volpone John · CIK 0002081729 · President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 265,305

F1 · kind: Sale of shares to cover personal income tax obligation upon settlement of restricted stock unit award.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $4.33 to $4.55, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3 · balance_after: Of the shares of common stock reported, 193,254 shares represent restricted stock units.

SEC source: 0001501697-26-000064 · wk-form4_1782937206.xml · derivative · entry 1

Gold Kelly · CIK 0002033333 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 110,000

Underlying: Common Stock · 110,000 shares

Expires 2036-07-01

F1 · derivative.exercise_date: The shares subject to the option shall vest in full on the one-year anniversary of the grant date, subject to the Reporting Person continuing to provide services through such date.

SEC source: 0001501697-26-000065 · wk-form4_1782937402.xml · nonDerivative · entry 1

KIRSKE DAVID · CIK 0001276750 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 167,750

F1 · kind: Sale of shares to cover personal income tax obligation upon settlement of restricted stock unit award.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $4.21 to $4.31, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3 · balance_after: Of the shares of common stock reported, 96,627 shares represent restricted stock units.

SEC source: 0001501697-26-000049 · wk-form4_1778702561.xml · nonDerivative · entry 1

KIRSKE DAVID · CIK 0001276750 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 176,293

F1 · kind: Sale of shares to cover personal income tax obligation upon settlement of restricted stock unit award.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $4.20 to $4.45, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3 · balance_after: Of the shares of common stock reported, 128,836 shares represent restricted stock units.

SEC source: 0001501697-26-000006 · wk-form4_1767647121.xml · derivative · entry 1

WYZGA MICHAEL S · CIK 0001201256 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 110,000 shares

Expires 2036-01-01

F1 · derivative.exercise_date: The shares subject to the option shall vest in full upon stockholder approval of an increase in the share reserve under the Companys Amended and Restated 2017 Equity Incentive Plan at the Companys 2026 annual meeting of stockholders, subject to the Reporting Person continuing to provide services through such date.

SEC source: 0001501697-26-000007 · wk-form4_1767647168.xml · derivative · entry 1

de Craecker Francoise · CIK 0001887843 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 110,000 shares

Expires 2036-01-01

F1 · derivative.exercise_date: The shares subject to the option shall vest in full upon stockholder approval of an increase in the share reserve under the Companys Amended and Restated 2017 Equity Incentive Plan at the Companys 2026 annual meeting of stockholders, subject to the Reporting Person continuing to provide services through such date.

SEC source: 0001501697-26-000005 · wk-form4_1767647080.xml · derivative · entry 1

Stewart Murray · CIK 0001723450 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 110,000 shares

Expires 2036-01-01

F1 · derivative.exercise_date: The shares subject to the option shall vest in full upon stockholder approval of an increase in the share reserve under the Companys Amended and Restated 2017 Equity Incentive Plan at the Companys 2026 annual meeting of stockholders, subject to the Reporting Person continuing to provide services through such date.

SEC source: 0001501697-26-000009 · wk-form4_1767819605.xml · derivative · entry 1

Bridger Gary · CIK 0001600049 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 110,000 shares

Expires 2036-01-01

F1 · derivative.exercise_date: The shares subject to the option shall vest in full upon stockholder approval of an increase in the share reserve under the Companys Amended and Restated 2017 Equity Incentive Plan at the Companys 2026 annual meeting of stockholders, subject to the Reporting Person continuing to provide services through such date.

SEC source: 0001276750-25-000004 · wk-form4_1761943312.xml · derivative · entry 1

KIRSKE DAVID · CIK 0001276750 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,552,769

Underlying: Common Stock · 1,552,769 shares

Expires 2035-08-12

F1 · derivative.exercise_date: Represents stock options granted to the Reporting Person on August 12, 2025, which were subject to a performance-based vesting condition that was satisfied on October 29, 2025. One third of the shares subject to the option shall vest on August 12, 2026, with the remainder vesting in equal installments each successive month thereafter for a period of 24 months, subject to the Reporting Person continuing to provide services through each such date.

SEC source: 0001339498-25-000004 · wk-form4_1761943322.xml · derivative · entry 1

Craig Adam R · CIK 0001339498 · Director · Executive Chairman

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,329,154

Underlying: Common Stock · 2,329,154 shares

Expires 2035-08-12

F1 · derivative.exercise_date: Represents stock options granted to the Reporting Person on August 12, 2025, which were subject to a performance-based vesting condition that was satisfied on October 29, 2025. One third of the shares subject to the option shall vest on August 12, 2026, with the remainder vesting in equal installments each successive month thereafter for a period of 24 months, subject to the Reporting Person continuing to provide services through each such date.

SEC source: 0002081729-25-000003 · wk-form4_1761943317.xml · derivative · entry 1

Volpone John · CIK 0002081729 · President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,329,154

Underlying: Common Stock · 2,329,154 shares

Expires 2035-08-12

F1 · derivative.exercise_date: Represents stock options granted to the Reporting Person on August 12, 2025, which were subject to a performance-based vesting condition that was satisfied on October 29, 2025. One third of the shares subject to the option shall vest on August 12, 2026, with the remainder vesting in equal installments each successive month thereafter for a period of 24 months, subject to the Reporting Person continuing to provide services through each such date.

SEC source: 0001501697-25-000035 · wk-form4_1761604837.xml · nonDerivative · entry 1

Craig Adam R · CIK 0001339498 · Director · Executive Chairman

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 376,087

F1 · shares: Consists of shares of the Issuer's common stock purchased in connection with the Issuer's public offering.

SEC source: 0001628280-25-040440 · wk-form4_1755217870.xml · derivative · entry 3

KIRSKE DAVID · CIK 0001276750 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 352,800

Underlying: Common Stock · 352,800 shares

Expires 2035-08-14

F2 · derivative.exercise_date: One half of the shares subject to the option shall vest on February 12, 2026, with the remainder vesting in equal installments in each successive month thereafter for a period of 12 months, subject to the Reporting Person continuing to provide services through each such date; provided that one half of the shares subject to the option shall vest immediately upon achievement of certain performance-based milestones prior to February 12, 2026.

SEC source: 0001628280-25-040440 · wk-form4_1755217870.xml · nonDerivative · entry 1

KIRSKE DAVID · CIK 0001276750 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 193,254

F1 · shares: Represents restricted stock units (RSUs) granted to the Reporting Person. One third of the RSUs shall vest on February 12, 2026, with the remainder vesting in equal installments in each successive quarter thereafter for a period of 12 months, subject to the Reporting Person continuing to provide services through each such date and contingent upon approval of the grant at the Issuer's 2026 Annual Meeting of Stockholders.

SEC source: 0001628280-25-040441 · wk-form4_1755217877.xml · derivative · entry 3

Craig Adam R · CIK 0001339498 · Director · Executive Chairman

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 529,201

Underlying: Common Stock · 529,201 shares

Expires 2035-08-14

F2 · derivative.exercise_date: One third of the shares subject to the option shall vest on August 12, 2026, with the remainder vesting in equal installments each successive month thereafter for a period of 24 months, subject to the Reporting Person continuing to provide services through each such date.

SEC source: 0001628280-25-040441 · wk-form4_1755217877.xml · nonDerivative · entry 1

Craig Adam R · CIK 0001339498 · Director · Executive Chairman

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 289,881

F1 · shares: Represents restricted stock units (RSUs) granted to the Reporting Person. One third of the RSUs shall vest on each of August 12, 2026, August 12, 2027 and August 12, 2028, subject to the Reporting Person continuing to provide services through each such date and contingent upon approval of the grant at the Issuer's 2026 Annual Meeting of Stockholders.

SEC source: 0001628280-25-040444 · wk-form4_1755217902.xml · derivative · entry 3

Volpone John · CIK 0002081729 · President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 529,201

Underlying: Common Stock · 529,201 shares

Expires 2035-08-14

F2 · derivative.exercise_date: One third of the shares subject to the option shall vest on August 12, 2026, with the remainder vesting in equal installments each successive month thereafter for a period of 24 months, subject to the Reporting Person continuing to provide services through each such date.

SEC source: 0001628280-25-040444 · wk-form4_1755217902.xml · nonDerivative · entry 1

Volpone John · CIK 0002081729 · President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 289,881

F1 · shares: Represents restricted stock units (RSUs) granted to the Reporting Person. One third of the RSUs shall vest on each of August 12, 2026, August 12, 2027 and August 12, 2028, subject to the Reporting Person continuing to provide services through each such date and contingent upon approval of the grant at the Issuer's 2026 Annual Meeting of Stockholders.

SEC source: 0001628280-25-040440 · wk-form4_1755217870.xml · derivative · entry 2

KIRSKE DAVID · CIK 0001276750 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,073,249

Underlying: Common Stock · 1,073,249 shares

Expires 2035-08-12

F2 · derivative.exercise_date: One half of the shares subject to the option shall vest on February 12, 2026, with the remainder vesting in equal installments in each successive month thereafter for a period of 12 months, subject to the Reporting Person continuing to provide services through each such date; provided that one half of the shares subject to the option shall vest immediately upon achievement of certain performance-based milestones prior to February 12, 2026.

SEC source: 0001628280-25-040441 · wk-form4_1755217877.xml · derivative · entry 2

Craig Adam R · CIK 0001339498 · Director · Executive Chairman

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,609,873

Underlying: Common Stock · 1,609,873 shares

Expires 2035-08-12

F2 · derivative.exercise_date: One third of the shares subject to the option shall vest on August 12, 2026, with the remainder vesting in equal installments each successive month thereafter for a period of 24 months, subject to the Reporting Person continuing to provide services through each such date.

SEC source: 0001628280-25-040444 · wk-form4_1755217902.xml · derivative · entry 2

Volpone John · CIK 0002081729 · President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,609,873

Underlying: Common Stock · 1,609,873 shares

Expires 2035-08-12

F2 · derivative.exercise_date: One third of the shares subject to the option shall vest on August 12, 2026, with the remainder vesting in equal installments each successive month thereafter for a period of 24 months, subject to the Reporting Person continuing to provide services through each such date.

SEC source: 0001628280-25-030489 · wk-form4_1749587118.xml · nonDerivative · entry 1

WYZGA MICHAEL S · CIK 0001201256 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,555

F1 · shares: Represents restricted stock units (RSUs) granted to the Reporting Person as an annual award for service on the Board of Directors. The RSUs will vest in full on the earlier of (i) the one-year anniversary of the grant date or (ii) the Issuer's next annual meeting of stockholders, subject to continued board service through the applicable vesting date. The RSUs will vest in full upon the occurrence of a change in control of the Issuer.

SEC source: 0001628280-25-030492 · wk-form4_1749587293.xml · nonDerivative · entry 1

MCGIRR DAVID W J · CIK 0001219023 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,722

F1 · shares: Represents restricted stock units (RSUs) granted to the Reporting Person as an annual award for service on the Board of Directors. The RSUs will vest in full on the earlier of (i) the one-year anniversary of the grant date or (ii) the Issuer's next annual meeting of stockholders, subject to continued board service through the applicable vesting date. The RSUs will vest in full upon the occurrence of a change in control of the Issuer.

SEC source: 0001628280-25-030504 · wk-form4_1749587446.xml · nonDerivative · entry 1

Stewart Murray · CIK 0001723450 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,883

F1 · shares: Represents restricted stock units (RSUs) granted to the Reporting Person as an annual award for service on the Board of Directors. The RSUs will vest in full on the earlier of (i) the one-year anniversary of the grant date or (ii) the Issuer's next annual meeting of stockholders, subject to continued board service through the applicable vesting date. The RSUs will vest in full upon the occurrence of a change in control of the Issuer.

SEC source: 0001628280-25-030503 · wk-form4_1749587436.xml · nonDerivative · entry 1

de Craecker Francoise · CIK 0001887843 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,722

F1 · shares: Represents restricted stock units (RSUs) granted to the Reporting Person as an annual award for service on the Board of Directors. The RSUs will vest in full on the earlier of (i) the one-year anniversary of the grant date or (ii) the Issuer's next annual meeting of stockholders, subject to continued board service through the applicable vesting date. The RSUs will vest in full upon the occurrence of a change in control of the Issuer.

SEC source: 0001628280-25-030502 · wk-form4_1749587426.xml · nonDerivative · entry 1

Bridger Gary · CIK 0001600049 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,722

F1 · shares: Represents restricted stock units (RSUs) granted to the Reporting Person as an annual award for service on the Board of Directors. The RSUs will vest in full on the earlier of (i) the one-year anniversary of the grant date or (ii) the Issuer's next annual meeting of stockholders, subject to continued board service through the applicable vesting date. The RSUs will vest in full upon the occurrence of a change in control of the Issuer.

SEC source: 0001628280-25-030500 · wk-form4_1749587415.xml · nonDerivative · entry 1

Woods Keith · CIK 0001996804 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,000

F1 · shares: Represents restricted stock units (RSUs) granted to the Reporting Person as an annual award for service on the Board of Directors. The RSUs will vest in full on the earlier of (i) the one-year anniversary of the grant date or (ii) the Issuer's next annual meeting of stockholders, subject to continued board service through the applicable vesting date. The RSUs will vest in full upon the occurrence of a change in control of the Issuer.

SEC source: 0001628280-25-034233 · wk-form4_1751574063.xml · nonDerivative · entry 1

Thoren Natasha Fay · CIK 0002070977 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,462

F1 · shares: Grant of restricted stock units to the Reporting Person under the Issuer's Amended and Restated 2017 Equity Incentive Plan with each restricted stock unit representing the right to receive one share of common stock on the applicable vesting date. No amount was paid upon the grant of the restricted stock units. The restricted stock units vest in three equal annual installments on May 10, 2026, May 10, 2027 and May 10, 2028, subject to the Reporting Person continuing to provide service as an employee of the Issuer through such date.

F2 · balance_after: The reported amount has been adjusted to reflect a correction to the number of shares beneficially owned by the Reporting Person, which was inadvertently overstated by 855 shares on the Form 3 filed on June 3, 2025.

SEC source: 0001628280-25-026864 · wk-form4_1747774254.xml · nonDerivative · entry 1

Baldry Mark · CIK 0001644137 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,337

F1 · shares: On May 16, 2025, the Reporting Person purchased shares of common stock through the Issuer's Amended and Restated 2017 Employee Stock Purchase Plan at a price of $2.482 per share.

SEC source: 0001628280-25-029113 · wk-form4a_1748984454.xml · nonDerivative · entry 1

Baldry Mark · CIK 0001644137 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,337

F1 · shares: On May 16, 2025, the Reporting Person purchased shares of common stock through the Issuer's Amended and Restated 2017 Employee Stock Purchase Plan at a price of $2.482 per share. Such transaction was exempt under both Rule 16b-3(d) and Rule 16b-3(c) of the Securities Exchange Act of 1934, as amended.

SEC source: 0001628280-25-005696 · wk-form4_1739567286.xml · nonDerivative · entry 1

DiBiase Mary · CIK 0001880179 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,140,980

F1 · shares: Grant of restricted stock units to the Reporting Person under the Issuer's Amended and Restated 2017 Equity Incentive Plan with each restricted stock unit representing the right to receive one share of common stock on the applicable vesting date. No amount was paid upon the grant of the restricted stock units. The restricted stock units vest in three equal annual installments on February 12, 2026, February 12, 2027 and February 12, 2028, subject to the Reporting Person continuing to provide service as an employee of the Issuer through such date.

SEC source: 0001628280-25-005702 · wk-form4_1739567322.xml · nonDerivative · entry 1

Mostafa Adam S. · CIK 0001738081 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 850,000

F1 · shares: Grant of restricted stock units to the Reporting Person under the Issuer's Amended and Restated 2017 Equity Incentive Plan with each restricted stock unit representing the right to receive one share of common stock on the applicable vesting date. No amount was paid upon the grant of the restricted stock units. The restricted stock units vest in three equal annual installments on February 12, 2026, February 12, 2027 and February 12, 2028, subject to the Reporting Person continuing to provide service as an employee of the Issuer through such date.

SEC source: 0001628280-25-005704 · wk-form4_1739567336.xml · nonDerivative · entry 1

Arbet-Engels Christophe · CIK 0001802615 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 864,207

F1 · shares: Grant of restricted stock units to the Reporting Person under the Issuer's Amended and Restated 2017 Equity Incentive Plan with each restricted stock unit representing the right to receive one share of common stock on the applicable vesting date. No amount was paid upon the grant of the restricted stock units. The restricted stock units vest in three equal annual installments on February 12, 2026, February 12, 2027 and February 12, 2028, subject to the Reporting Person continuing to provide service as an employee of the Issuer through such date.

SEC source: 0001628280-25-005700 · wk-form4_1739567310.xml · nonDerivative · entry 1

Ragan Paula · CIK 0001769914 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,337,386

F1 · shares: Grant of restricted stock units to the Reporting Person under the Issuer's Amended and Restated 2017 Equity Incentive Plan with each restricted stock unit representing the right to receive one share of common stock on the applicable vesting date. No amount was paid upon the grant of the restricted stock units. The restricted stock units vest in three equal annual installments on February 12, 2026, February 12, 2027 and February 12, 2028, subject to the Reporting Person continuing to provide service as an employee of the Issuer through such date.

SEC source: 0001628280-25-005698 · wk-form4_1739567298.xml · nonDerivative · entry 3

Baldry Mark · CIK 0001644137 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 729,173

F2 · balance_after: Grant of restricted stock units to the Reporting Person under the Issuer's Amended and Restated 2017 Equity Incentive Plan with each restricted stock unit representing the right to receive one share of common stock on the applicable vesting date. No amount was paid upon the grant of the restricted stock units. The restricted stock units vest in three equal annual installments on February 12, 2026, February 12, 2027 and February 12, 2028, subject to the Reporting Person continuing to provide service as an employee of the Issuer through such date.

SEC source: 0001628280-25-002706 · wk-form4_1738019716.xml · nonDerivative · entry 2

DiBiase Mary · CIK 0001880179 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 490,980

F2 · shares: These transactions were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 28, 2024.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $0.4472 to $0.47, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001628280-25-002708 · wk-form4_1738019736.xml · nonDerivative · entry 2

Mostafa Adam S. · CIK 0001738081 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F2 · shares: These transactions were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 28, 2024.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $0.447 to $0.47, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001628280-25-002707 · wk-form4_1738019726.xml · nonDerivative · entry 2

Baldry Mark · CIK 0001644137 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 94,123

F2 · shares: These transactions were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 28, 2024.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $0.4475 to $0.47, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001628280-25-002709 · wk-form4_1738019748.xml · nonDerivative · entry 2

Ragan Paula · CIK 0001769914 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,087,386

F2 · shares: These transactions were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 28, 2024.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $0.4468 to $0.47, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001628280-25-002705 · wk-form4_1738019705.xml · nonDerivative · entry 2

Arbet-Engels Christophe · CIK 0001802615 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,207

F2 · shares: These transactions were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 28, 2024.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $0.4478 to $0.47, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001628280-25-002706 · wk-form4_1738019716.xml · nonDerivative · entry 1

DiBiase Mary · CIK 0001880179 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 513,238

F1 · shares: Represents shares earned upon the vesting of performance-based restricted stock units. The Compensation Committee of the Board of Directors of the Issuer certified the achievement of a performance condition, which occurred upon the acceptance by the European Medicines Agency of the Issuer's Marketing Authorization Application for mavorixafor for the treatment of WHIM syndrome.

SEC source: 0001628280-25-002708 · wk-form4_1738019736.xml · nonDerivative · entry 1

Mostafa Adam S. · CIK 0001738081 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 74,773

F1 · shares: Represents shares earned upon the vesting of performance-based restricted stock units. The Compensation Committee of the Board of Directors of the Issuer certified the achievement of a performance condition, which occurred upon the acceptance by the European Medicines Agency of the Issuer's Marketing Authorization Application for mavorixafor for the treatment of WHIM syndrome.

SEC source: 0001628280-25-002707 · wk-form4_1738019726.xml · nonDerivative · entry 1

Baldry Mark · CIK 0001644137 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 123,282

F1 · shares: Represents shares earned upon the vesting of performance-based restricted stock units. The Compensation Committee of the Board of Directors of the Issuer certified the achievement of a performance condition, which occurred upon the acceptance by the European Medicines Agency of the Issuer's Marketing Authorization Application for mavorixafor for the treatment of WHIM syndrome.

SEC source: 0001628280-25-002709 · wk-form4_1738019748.xml · nonDerivative · entry 1

Ragan Paula · CIK 0001769914 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,163,859

F1 · shares: Represents shares earned upon the vesting of performance-based restricted stock units. The Compensation Committee of the Board of Directors of the Issuer certified the achievement of a performance condition, which occurred upon the acceptance by the European Medicines Agency of the Issuer's Marketing Authorization Application for mavorixafor for the treatment of WHIM syndrome.

SEC source: 0001628280-25-002705 · wk-form4_1738019705.xml · nonDerivative · entry 1

Arbet-Engels Christophe · CIK 0001802615 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,831

F1 · shares: Represents shares earned upon the vesting of performance-based restricted stock units. The Compensation Committee of the Board of Directors of the Issuer certified the achievement of a performance condition, which occurred upon the acceptance by the European Medicines Agency of the Issuer's Marketing Authorization Application for mavorixafor for the treatment of WHIM syndrome.

SEC source: 0001628280-24-048467 · wk-form4_1732051877.xml · nonDerivative · entry 1

Ragan Paula · CIK 0001769914 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 993,919

F1 · shares: These transactions were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 28, 2024.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $0.364 to $0.41, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001628280-25-005698 · wk-form4_1739567298.xml · nonDerivative · entry 2

Baldry Mark · CIK 0001644137 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 129,173

F1 · balance_after: The Reporting Person purchased shares of common stock through the Issuer's Amended and Restated 2017 Employee Stock Purchase Plan. Such purchases were inadvertently omitted from previous Form 4 filings and are now being reported.

SEC source: 0001628280-24-042941 · wk-form4_1729112077.xml · nonDerivative · entry 1

Ragan Paula · CIK 0001769914 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,025,816

F1 · shares: These transactions were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 28, 2024.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $0.5424 to $0.5806, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.